Metformin and breast cancer: an opportunity for pharmacogenetics
Elisabet Cuyàs1Metabolism and Cancer Group, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology–Girona Biomedical Research Institute, Girona, Spain, Begoña Martin-Castillo2Clinical Research Unit, Catalan Institute of Oncology–Girona, Girona, Spain,*, Javier A. Menendez1Metabolism and Cancer Group, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology–Girona Biomedical Research Institute, Girona, Spain,*
1Metabolism and Cancer Group, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology–Girona Biomedical Research Institute, Girona, Spain
2Clinical Research Unit, Catalan Institute of Oncology–Girona, Girona, Spain
* On behalf of the METTEN study group
Received: June 7, 2022Accepted: July 11, 2022Published: July 18, 2022